Source author record

Frank Bretz

Frank Bretz appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Methodology Applications

Catalog footprint

What is connected

10works

2topics

4close collaborators

Actions

Connect this record

Open graph Browse works

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2022arXiv

Confidence Sets for a level set in linear regression

Regression modeling is the workhorse of statistics and there is a vast literature on estimation of the regression function. It is realized in recent years that in regression analysis the ultimate aim may be the estimation of a level set of the regression function, instead of the estimation of the regression function itself. The published work on estimation of the level set has thus far focused mainly on nonparametric regression, especially on point estimation. In this paper, the construction of confidence sets for the level set of linear regression is considered. In particular, $1-α$ level upper, lower and two-sided confidence sets are constructed for the normal-error linear regression. It is shown that these confidence sets can be easily constructed from the corresponding $1-α$ level simultaneous confidence bands. It is also pointed out that the construction method is readily applicable to other parametric regression models where the mean response depends on a linear predictor through a monotonic link function, which include generalized linear models, linear mixed models and generalized linear mixed models. Therefore the method proposed in this paper is widely applicable. Examples are given to illustrate the method.

preprint2022arXiv

Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

The COVID-19 pandemic continues to affect the conduct of clinical trials globally. Complications may arise from pandemic-related operational challenges such as site closures, travel limitations and interruptions to the supply chain for the investigational product, or from health-related challenges such as COVID-19 infections. Some of these complications lead to unforeseen intercurrent events in the sense that they affect either the interpretation or the existence of the measurements associated with the clinical question of interest. In this article, we demonstrate how the ICH E9(R1) Addendum on estimands and sensitivity analyses provides a rigorous basis to discuss potential pandemic-related trial disruptions and to embed these disruptions in the context of study objectives and design elements. We introduce several hypothetical estimand strategies and review various causal inference and missing data methods, as well as a statistical method that combines unbiased and possibly biased estimators for estimation. To illustrate, we describe the features of a stylized trial, and how it may have been impacted by the pandemic. This stylized trial will then be re-visited by discussing the changes to the estimand and the estimator to account for pandemic disruptions. Finally, we outline considerations for designing future trials in the context of unforeseen disruptions.

preprint2020arXiv

Clinical trials impacted by the COVID-19 pandemic: Adaptive designs to the rescue?

Very recently the new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified and the coronavirus disease 2019 (COVID-19) declared a pandemic by the World Health Organization. The pandemic has a number of consequences for the ongoing clinical trials in non-COVID-19 conditions. Motivated by four currently ongoing clinical trials in a variety of disease areas we illustrate the challenges faced by the pandemic and sketch out possible solutions including adaptive designs. Guidance is provided on (i) where blinded adaptations can help; (ii) how to achieve type I error rate control, if required; (iii) how to deal with potential treatment effect heterogeneity; (iv) how to utilize early readouts; and (v) how to utilize Bayesian techniques. In more detail approaches to resizing a trial affected by the pandemic are developed including considerations to stop a trial early, the use of group-sequential designs or sample size adjustment. All methods considered are implemented in a freely available R shiny app. Furthermore, regulatory and operational issues including the role of data monitoring committees are discussed.

preprint2020arXiv

Simultaneous Confidence Tubes for Comparison of Several Multivariate Linear Regression Models

Much of the research on multiple comparison and simultaneous inference in the past sixty years or so has been for the comparisons of several population means. Spurrier (1999) seems to be the first to study the multiple comparison of several simple linear regression lines by using simultaneous confidence bands. In this paper, the work of Liu et al. (2004) for finite comparisons of several univariate linear regression models by using simultaneous confidence bands has been extended to finite comparison of several multivariate linear regression models by using simultaneous confidence tubes. We show how simultaneous confidence tubes can be constructed to allow more informative inferences for the comparison of several multivariate linear regression models than the current approach of hypotheses testing. The methodologies are illustrated with examples.

preprint2016arXiv

Equivalence of dose response curves

This paper investigates the problem whether the difference between two parametric models $m_1,m_2$ describing the relation between a response variable and several covariates in two different groups is practically irrelevant, such that inference can be performed on the basis of the pooled sample. Statistical methodology is developed to test the hypotheses $H_0 : d(m_1,m_2)\geq ε$ versus $H_1 : d(m_1,m_2) < ε$ to demonstrate equivalence between the two regression curves $m_1,m_2$ for a pre-specified threshold $ε$, where $d$ denotes a distance measuring the distance between $m_1$ and $m_2$. Our approach is based on the asymptotic properties of a suitable estimator $d(\hat{m}_1; \hat{m}_2)$ of this distance. In order to improve the approximation of the nominal level for small sample sizes a bootstrap test is developed, which addresses the specific form of the interval hypotheses. In particular, data has to be generated under the null hypothesis, which implicitly defines a manifold for the parameter vector. The results are illustrated by means of a simulation study and a data example. It is demonstrated that the new methods substantially improve currently available approaches with respect to power and approximation of the nominal level.

preprint2016arXiv

Optimal designs for active controlled dose finding trials with efficacy-toxicity outcomes

Nonlinear regression models addressing both efficacy and toxicity outcomes are increasingly used in dose-finding trials, such as in pharmaceutical drug development. However, research on related experimental design problems for corresponding active controlled trials is still scarce. In this paper we derive optimal designs to estimate efficacy and toxicity in an active controlled clinical dose finding trial when the bivariate continuous outcomes are modeled either by polynomials up to degree 2, the Michaelis- Menten model, the Emax model, or a combination thereof. We determine upper bounds on the number of different doses levels required for the optimal design and provide conditions under which the boundary points of the design space are included in the optimal design. We also provide an analytical description of the minimally supported $D$-optimal designs and show that they do not depend on the correlation between the bivariate outcomes. We illustrate the proposed methods with numerical examples and demonstrate the advantages of the $D$-optimal design for a trial, which has recently been considered in the literature.

preprint2015arXiv

Model Selection versus Model Averaging in Dose Finding Studies

Phase II dose finding studies in clinical drug development are typically conducted to adequately characterize the dose response relationship of a new drug. An important decision is then on the choice of a suitable dose response function to support dose selection for the subsequent Phase III studies. In this paper we compare different approaches for model selection and model averaging using mathematical properties as well as simulations. Accordingly, we review and illustrate asymptotic properties of model selection criteria and investigate their behavior when changing the sample size but keeping the effect size constant. In a large scale simulation study we investigate how the various approaches perform in realistically chosen settings. Finally, the different methods are illustrated with a recently conducted Phase II dosefinding study in patients with chronic obstructive pulmonary disease.

preprint2014arXiv

Designing dose finding studies with an active control for exponential families

In a recent paper Dette et al. (2014) introduced optimal design problems for dose fnding studies with an active control. These authors concentrated on regression models with normal distributed errors (with known variance) and the problem of determining optimal designs for estimating the smallest dose, which achieves the same treatment effect as the active control. This paper discusses the problem of designing active-controlled dose fnding studies from a broader perspective. In particular, we consider a general class of optimality criteria and models arising from an exponential family, which are frequently used analyzing count data. We investigate under which circumstances optimal designs for dose fnding studies including a placebo can be used to obtain optimal designs for studies with an active control. Optimal designs are constructed for several situations and the differences arising from different distributional assumptions are investigated in detail. In particular, our results are applicable for constructing optimal experimental designs to analyze active-controlled dose fnding studies with discrete data, and we illustrate the efficiency of the new optimal designs with two recent examples from our consulting projects.

preprint2013arXiv

Model-based dose finding under model uncertainty using general parametric models

Statistical methodology for the design and analysis of clinical Phase II dose response studies, with related software implementation, are well developed for the case of a normally distributed, homoscedastic response considered for a single timepoint in parallel group study designs. In practice, however, binary, count, or time-to-event endpoints are often used, typically measured repeatedly over time and sometimes in more complex settings like crossover study designs. In this paper we develop an overarching methodology to perform efficient multiple comparisons and modeling for dose finding, under uncertainty about the dose-response shape, using general parametric models. The framework described here is quite general and covers dose finding using generalized non-linear models, linear and non-linear mixed effects models, Cox proportional hazards (PH) models, etc. In addition to the core framework, we also develop a general purpose methodology to fit dose response data in a computationally and statistically efficient way. Several examples, using a variety of different statistical models, illustrate the breadth of applicability of the results. For the analyses we developed the R add-on package DoseFinding, which provides a convenient interface to the general approach adopted here.

preprint2011arXiv

Response-adaptive dose-finding under model uncertainty

Dose-finding studies are frequently conducted to evaluate the effect of different doses or concentration levels of a compound on a response of interest. Applications include the investigation of a new medicinal drug, a herbicide or fertilizer, a molecular entity, an environmental toxin, or an industrial chemical. In pharmaceutical drug development, dose-finding studies are of critical importance because of regulatory requirements that marketed doses are safe and provide clinically relevant efficacy. Motivated by a dose-finding study in moderate persistent asthma, we propose response-adaptive designs addressing two major challenges in dose-finding studies: uncertainty about the dose-response models and large variability in parameter estimates. To allocate new cohorts of patients in an ongoing study, we use optimal designs that are robust under model uncertainty. In addition, we use a Bayesian shrinkage approach to stabilize the parameter estimates over the successive interim analyses used in the adaptations. This approach allows us to calculate updated parameter estimates and model probabilities that can then be used to calculate the optimal design for subsequent cohorts. The resulting designs are hence robust with respect to model misspecification and additionally can efficiently adapt to the information accrued in an ongoing study. We focus on adaptive designs for estimating the minimum effective dose, although alternative optimality criteria or mixtures thereof could be used, enabling the design to address multiple objectives.